Press release
Consistent Innovation To Boost The Neurological Biomarkers Market
The University of British Columbia and the Karolinska Institute in Sweden have set up biobanks that provide necessary resources and information for biomedical research. Alzheimer's is the most common form of dementia affecting 12 million people. Neuroimaging and neuropsychological probes can help predict Alzheimer before behavioral tests diagnose. Thus pre-assessment tests such as Positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) are driving the demand for neurological biomarkers.
The introduction of newer neurological biomarkers is expected to play a crucial role in helping neuropathologists in the characterization and selection of suitable treatment strategies. Moreover, with the advent of telehealth and personalized medicine, there is an emerging trend of single-cell biosensors as it may help integrating large-scale clinical and molecular information.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/16303
These biomarkers are used in patients suffering from acute ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage and traumatic brain injury. Recovery from such neurocritical disease depends on how well the patient mitigates. In such situations, procurement of imaging studies or a good examination may be delayed due to the complexities involved. This shortcoming has further fueled the demand for biomarkers. The market is also experiencing recent trends with the researches undertaken on novel radiotracers, miRNA, and integration of systems biology into routine biomarker validation.
The neurological market is expected to witness growth owing to the various technological developments, the expansion in application and rise in the incidence of neurological disorders such as Alzheimer's, Parkinson's and stroke. But the industry has certain restraints such as reproduction of positive trial results, the absence of pre-analytical tests and failure to investigate the efficiency of the biomarker as compared to previous one.
Furthermore, the demand for these biomarkers is expected to propel as the demand for neurological care is increasing. In America, there are around 5.4 million people diagnosed with Alzheimer's disease. The number is expected to triple to 16 million by 2050. The demand for procedural specialties is more as compared to on procedural specialties. This statement can be justified by the fact that the Medicare payment grew by 84% for procedural specialties and only 48% for non-procedural specialties.
For the entire list of market players, request for Table of Content here@ https://www.persistencemarketresearch.com/toc/16303
Neurological Biomarkers Market: Segmentation
On the basis of imaging techniques
Transcranial magnetic stimulation (TMS)
Diffusion tensor imaging (DTI)
Conventional structural MRI (sMRI)
Functional magnetic resonance imaging (fMRI)
Positron emission tomography (PET)
On the basis of application
Proteomics based biomarkers
Genomic based biomarkers
Imaging based biomarkers
Metabolic based biomarkers
On the basis of indication
Alzheimer's disease (AD)
Multiple sclerosis (MS)
Parkinson's disease (PD)
Autism spectrum disorder (ASD)
On the basis of end-user
Hospitals
Clinics
Diagnostic and research laboratories
On the basis of services
Sample preparation
Assay development
Biomarker validation and testing
Pre-Book Right Now for Exclusive Analyst Support@ https://www.persistencemarketresearch.com/checkout/16303
In terms of geography, the global neurological biomarkers market has been divided into five regions including North- America, Asia- Pacific and Middle-East & Africa, Latin America and Europe. North America has a major revenue share in the neurological biomarkers industry as many prominent market players are present in this region, the number of R&D projects carried out and the government funding received by academic universities to undertake research.
For instance in August 2015, researchers, patients and various non-profit organizations participated in the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) study. The USD 100 million project aims to study the utility of amyloid PET imaging to diagnose dementia, Alzheimer's and cognitive impairment.
Complete Report Details@ https://www.persistencemarketresearch.com/market-research/neurological-biomarkers-market.asp
Asia-Pacific is the fastest growing region as the region offers huge population base, high incidence rate of neurological abnormalities, entry of new market players and huge aging population. In developing economies such as India and China, new industry players are trying to establish their market presence by developing the generic version of the biomarker, through contract research organizations. This has further helped in reducing the manufacturing cost for the company and other production related cost.
Key players in the neurological biomarkers industry are Myriad RBM, Proteome Sciences, QIAGEN, Thermo Fisher Scientific, AbaStar MDx, Acumen Pharmaceuticals, Abiant, Aepodia, Athena Diagnostics, ImmunArray, Quanterix and Cisbio Bioassays.
Related Reports:
Postoperative Pain Management Market - https://www.persistencemarketresearch.com/market-research/postoperative-pain-management-market.asp
Contact Us:
Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Consistent Innovation To Boost The Neurological Biomarkers Market here
News-ID: 2664669 • Views: …
More Releases from Persistence Market Research
Europe Calf Milk Replacer Market to Reach US$1,657.2 Mn by 2032 | Driven by Risi …
The Europe calf milk replacer market is poised for significant growth over the coming years. The market size is projected to reach US$1,018.6 million in 2025 and is anticipated to expand to US$1,657.2 million by 2032, registering a robust compound annual growth rate (CAGR) of 7.2% during the forecast period from 2025 to 2032. The growth trajectory is driven by the increasing awareness among dairy farmers regarding the nutritional requirements…
Croscarmellose Sodium Market to Reach $487 Mn by 2032, Driven by Rising Pharma D …
The global croscarmellose sodium market is projected to witness significant expansion over the forecast period, reflecting the growing adoption of pharmaceutical excipients across diverse applications. Valued at approximately US$ 288.7 million in 2025, the market is expected to reach US$ 487.0 million by 2032, registering a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032. This growth trajectory is driven primarily by increasing demand for orally disintegrating tablets…
Europe Egg Replacement Ingredients Market to Reach $1,711.1 Mn by 2032, Driven b …
The Europe egg replacement ingredients market is witnessing significant expansion, driven by the increasing adoption of plant-based diets and rising consumer awareness regarding health and wellness. The market size is projected to reach US$ 952.2 million in 2025 and is expected to surge to US$ 1,711.1 million by 2032, registering a robust CAGR of 8.7% over the forecast period from 2025 to 2032. The growing demand for clean-label products, vegan…
Kraft Paper Market to Reach US$ 25.0 Billion by 2032: Growth Driven by Rising De …
The global Kraft Paper market is undergoing significant expansion, driven by the accelerating shift toward eco-friendly packaging materials and the rising global awareness surrounding sustainability. As industries worldwide transition from plastic-based packaging to biodegradable alternatives, kraft paper has emerged as one of the most sought-after materials due to its strength, recyclability, and versatility.
According to the latest study by Persistence Market Research, the global Kraft Paper market size is projected to…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
